Open original FDA record ↗Recall record
- FDA identifier
- Z-2754-2019
- Company in FDA record
- Siemens Healthcare Diagnostics, Inc
- FDA record creation date
- Sep 26, 2019
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class II
Reason stated in the source
Atellica IM anti-CCP IgG (aCCP) Test Definition (TDef) Mitigation Failure-reagent carryover mitigation for the Testosterone II (TSTII) assay is unable to be completed as defined in the aCCP Test Definition (TDef). The issue occurs on an Atellica IM Analyzer and is isolated to TDef Version 1.0. FOR OUS: Atellica IM anti-CCP IgG (aCCP) and Pregnancy-Associated Plasma Protein-A (PAPP-A) Test Definition (TDef) Mitigation Failure
Source facts
- Action
- Siemens Healthcare Urgent Medical Device Correction, AIMC 19-02.A.US sent to US customers on August 14, 2019 for delivery on August 15, 2019. Urgent Field Safety Notice, AIMC 19-02.A.OUS was sent out to the country (OUS) organizations on August 13, 2019 to customers outside the United States (US). The customer distribution included all customers that have received both Atellica IM anti-CCP IgG (aCCP) and Atellica IM Testosterone II (US and OUS) and/or both Atellica IM Pregnancy-Associated Plasma Protein-A (PAPP-A) and Atellica IM Testosterone II (OUS only) The letters inform customers that Siemens Healthcare Diagnostics has confirmed the reagent carryover mitigation for the Testosterone II assay is unable to be completed as defined in the aCCP Test Definition (US and OUS) and PAPP-A Test Definition (OUS only). The communications provide options to maintain continuous workflow. If you have any questions, contact your local Siemens Healthineers technical support representative
- Initiated
- 2019-08-14
- Root cause
- Under Investigation by firm
- Terminated
- 2021-07-28
- Distribution
- Worldwide distribution - US Nationwide distribution including the states of CA, FL, KY, NH, TX and countries of Austria¿¿¿¿¿¿¿¿ Curacao,¿St¿Eus Czech¿Republic¿ Denmark¿¿¿¿¿¿¿¿ France¿¿¿¿¿¿¿¿¿ Germany¿¿¿¿¿¿¿¿ Greece¿¿¿¿¿¿¿¿¿ Italy¿¿¿¿¿¿¿¿¿¿ Poland¿¿¿¿¿¿¿¿¿ Slovakia¿¿¿¿¿¿¿ Spain¿¿¿¿¿¿¿¿¿¿ Switzerland¿¿¿¿ U.A.E.¿¿¿¿¿¿¿¿¿
- Recall number
- Z-2754-2019
- Recall status
- Terminated
- CDRH record ID
- 176028
- FDA record created
- 2019-09-26
- Recall event number
- 83653